Sivem ezetimibe 10 mg tablets: One lot recalled as some bottles may contain perindopril 4 mg tablets
Summary
Product: Sivem ezetimibe 10 mg tablets
Issue: Health products – Product safety
What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance. Seek immediate medical attention if you are experiencing serious side effects, including symptoms of a severe allergic reaction, such as difficulty breathing or swallowing or severe swelling of the lips, mouth or throat.
Affected products
Product
DIN
Lot number
Expiry date
Sivem ezetimibe 10 mg tablets
02429659
100063638
2026-07-31
Issue
Sivem Pharmaceuticals ULC is recalling one lot of Sivem ezetimibe 10 mg tablets because some bottles may also contain perindopril 4 mg tablets. Taking perindopril when prescribed ezetimibe may pose serious health risks.
Ezetimibe is a prescription drug used by adults and children 10 years of age and older to lower cholesterol and other fats in the blood. Perindopril is a prescription drug used in adults to treat high blood pressure.
Patients not normally prescribed perindopril may experience side effects such as a drop in blood pressure, dizziness, light-headedness or fainting. Other possible effects could include headache, cough, or gastrointestinal discomfort (e.g., nausea, vomiting or diarrhea). The risk can be higher in people with low blood pressure, kidney problems, or those taking other medications that affect blood pressure. Patients unknowingly taking a medication could also have a severe allergic reaction to that medication.
Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified.
What you should do
Check your medication bottle to ensure it only contains Sivem ezetimibe 10 mg tablets.
Sivem ezetimibe 10 mg is a white oblong tablet, with '93' stamped on one side and 'A11' on the other.
Perindopril 4 mg is a spotted light green oblong tablet, with '4' stamped on one side and nothing stamped on the other. The tablet is scored (indented) on both middle edges.
If the bottle contains any unusual tablets, or if you are unsure, return it to your pharmacy immediately. Your pharmacist will check the tablets and provide you with a replacement, if needed.
If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance.
Seek immediate medical attention if you are experiencing serious side effects (e.g., dizziness, light-headedness or fainting, or severe allergic reaction).
If you have questions about this recall, contact Sivem Pharmaceuticals by calling 1-855-757-4836 or by emailing drugsafety@mckesson.ca.
Report any health product-related side effects or complaints to Health Canada.
Sivem ezetimibe 10 mg is a white oblong tablet, with '93' stamped on one side and 'A11' on the other.
Perindopril 4 mg is a spotted light green oblong tablet, with '4' stamped on one side and nothing stamped on the other. The tablet is scored (indented) on both middle edges.
Additional information for health professionals:
Health care professionals, such as pharmacists, should check bottles of Sivem ezetimibe 10 mg tablets before dispensing to ensure they do not contain perindopril 4 mg tablets. Report any unusual bottles or other issues to the company and to Health Canada.
Également disponible en français
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
a day ago
- Malaysian Reserve
ClariMed Inc. Acquires We Are Human, Expanding Growth into Southeast Market
We Are Human's Expert Team and Atlanta-Based Usability Lab Join ClariMed's Growing Network; Founder Annmarie Nicolson Appointed as Principal CHADDS FORD, Pa., Aug. 12, 2025 /CNW/ — ClariMed, Inc., a global leader in human-centered medical device development and regulatory services, today announced the strategic acquisition of We Are Human, a UK and US-based consultancy specializing in user-focused design and research in MedTech innovation. The acquisition expands ClariMed's geographic reach into the Southeast through We Are Human's state-of-the-art Atlanta research facility while advancing the company's mission to enable innovative, human-centered medical technologies and make them accessible to communities that need them. Annmarie Nicolson, founder of We Are Human, will join ClariMed as Principal, bringing her extensive experience in early-stage formative research, contextual inquiry, and UX research for MedTech innovation to the leadership team. The acquisition brings the complete We Are Human team and their Atlanta research facility into the ClariMed family, expanding the company's presence in the Southeast region. 'This acquisition represents our continued commitment to our user-centered foundation while expanding our reach and strengthening our capabilities,' said Kelley Kendle, CEO of ClariMed. 'Regional variability allows us to better address our patients' needs and advance our mission to make medical technology safer, more intuitive, and more impactful for the people who need it most. This isn't just a merger of capabilities — it's a deep alignment of values.' The acquisition strengthens ClariMed's position as an integrated medical device services partner, expanding specialized expertise in user experience research, regulatory compliance, and design validation across both US and UK markets. We Are Human brings ISO 13485 certification and extensive experience with IEC-62366 and FDA Guidance requirements, having conducted research with hundreds of healthcare professionals, lay persons and diverse patient groups. The Atlanta laboratory will serve as ClariMed's newest research facility, offering access to diverse study populations in the Southeast while supporting the company's growing client base. 'Joining ClariMed represents an exciting opportunity to amplify our impact in healthcare through human-centered research and design,' said Annmarie. 'Both organizations have a long-standing commitment to putting users first and creating products that truly make a difference in people's lives. This shared dedication to excellence and user-centered principles positions us to deliver even more meaningful solutions- both to our clients and, to the patients and healthcare providers who rely on innovative medical technology every day.' The integration of We Are Human establishes ClariMed's first Southeast location, joining strategic offices across the United States and internationally, including Chadds Ford, PA; Cambridge, MA; San Jose, CA; Cambridge, UK; Leeds, UK; and now Atlanta, GA. This expanded geographic network enhances ClariMed's ability to serve global clients while accessing diverse talent pools and participant populations for user research and usability testing. This acquisition aligns with ClariMed's growth strategy of building comprehensive, human-centered solutions for medical device development. The combined expertise of both organizations positions ClariMed to better serve pharmaceutical and medical device manufacturers seeking to accelerate time to market while enhancing patient safety and user experience. About ClariMed ClariMed is a human-centered development and regulatory practice for medical products developed by pharmaceutical and medical device manufacturers. Our best-of-breed professional services cultivate innovation while ensuring the safe and effective use of medical products. With offices across the United States and United Kingdom, ClariMed delivers comprehensive solutions that integrate human factors at the core of device development and regulatory pathways. Visit us at About We Are Human Founded in 2020, We Are Human is an ISO 13485 certified consultancy, based in the UK and US specializing in Human Factors, User Research and UX, with deep expertise in human-centered research and design for healthcare. The company was founded on the belief that human needs should be at the heart of design, striving to improve quality of life, health, and wellbeing through product development. We Are Human brings extensive experience in Human Factors and Usability Engineering standards and regulatory requirements for medical device development, including IEC-62366 and FDA Guidance, with a track record of collaborating with clients across Medical Devices, Combination Products, FemTech, Digital Health and over-the-counter (OTC) products. For media inquiries, please contact: press@
Malaysian Reserve
02-08-2025
- Malaysian Reserve
Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks
OTTAWA, ON, Aug. 1, 2025 /CNW/ – Summary Product: Unauthorized injectable peptide drugs Issue: Health products – Unauthorized product; Product safety What to do: Consult a healthcare professional if you have used an unauthorized injectable drug on the list below and have health concerns. Do not buy or use unauthorized drugs. Only buy prescription drugs from licensed pharmacies. Read product labels to confirm a product has been authorized for sale by Health Canada. Affected products Unauthorized injectable peptide drugs, including: • AOD9604 • ARA 290 • Bremelanotide • Bronchogen • BPC-157 • CJC-1295 • Cortagen • DSIP • Epitalon • GHK, GHK-Cu • GHRP 2 • GHRP 6 • GLP-1 (7-37) • Gonadorelin • Hexarelin • HGH, HGH Fragment • Humanine • Ipamoreline • Kisspeptin • KK-23 • Livagen • LL-37 • Melanotan 1 • Melanotan II • NR-7 • Ovagen • Pal-GHK • Pinealon • PNC-27 • Prostamax • QS-13 • Retatrutide • Selank • Semax • Sermorelin • SS-31 • Tesamorelin • Thymosin alpha • Thymosin-β4 (TB4 or TB-500) • Tirzepatide • Vilon • VIP IssueHealth Canada is warning the public of seized unauthorized injectable peptide drugs from Canada Peptide. The products were being sold via the company's website. Peptide drugs affect the body's functions and are often used for bodybuilding, anti-aging, or enhancing athletic performance. Injectable peptides are regulated as prescription drugs in Canada. Health Canada has not authorized any of the products that were seized or sold on the company's website, which means that they have not been assessed for safety, efficacy, and quality. Selling unauthorized drugs is illegal in Canada. Prescription drugs should only be used under the care of a healthcare professional because they are used to treat specific conditions and may cause serious side effects. Unauthorized injectable drugs may: Cause infectionallergic reactions, and other poor outcomes. Interact with other medications an individual might be taking. Contain high-risk ingredients, additives, or contaminants that may or may not be listed on the label. Not have been manufactured or stored safely. Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety, including communicating updates, if needed. What you should do Consult a health care professional (physician, nurse practitioner, pharmacist) if you have used an unauthorized injectable drug and have health concerns. Follow municipal or regional guidelines on how to dispose of chemicals and other hazardous waste or return the product to your local pharmacy for proper disposal. Only buy prescription drugs from licensed pharmacies. Be aware of the risks of buying health products online. Do not buy or use unauthorized drugs. You can read product labels to confirm the product has been authorized for sale by Health Canada. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database. Report any health product-related side effects or complaints to Health Canada. Également disponible en français
Malaysian Reserve
25-07-2025
- Malaysian Reserve
CIBC Recognized as a Leading Workplace for Disability Inclusion
TORONTO, July 25, 2025 /CNW/ – CIBC announced today it has been recognized as a Best Place to Work for Disability Inclusion after earning a top score on the 2025 Canada Disability Index®. This recognition underscores CIBC's ongoing commitment to matching talent to opportunity and promoting a workplace where all team members can flourish. The Disability Index® is a leading third-party benchmarking tool for workplace disability inclusion, and measures performance across key areas such as culture and leadership, enterprise-wide access, employment practices, community engagement, and supplier inclusion. 'At CIBC, inclusion is the cornerstone of our bank's culture. Building a workforce that reflects the clients and communities we serve allows for unique perspectives, experiences, and drives innovation,' said Sandy Sharman, Group Head, People, Culture and Brand, CIBC. 'This recognition reinforces our commitment to supporting our team members and empowering them to achieve their ambitions.' By achieving this distinction, CIBC joins hundreds of global organizations dedicated to advancing accessibility and supporting 1.3 billion people with disabilities worldwide1. To learn more about our commitments, visit Accessibility at CIBC. About CIBC CIBC is a leading North American financial institution with 14 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world. Ongoing news releases and more information about CIBC can be found at _____________________1 World Health Organization. 'Disability and Health.' WHO, 13 March 2023.
